S-1/A: Silo Pharma Engages H.C. Wainwright as Exclusive Underwriter for Securities Offerings

Silo Pharma enters into an agreement with H.C. Wainwright & Co. to serve as the exclusive underwriter, agent, or advisor for any securities offerings during the term of the agreement.

Summary

• Silo Pharma has engaged H.C. Wainwright & Co., LLC as its exclusive underwriter, agent, or advisor for any securities offerings.
• This agreement covers various offerings, including at-the-market (ATM) facilities.
• The terms of each offering will be mutually agreed upon, and Silo Pharma is not obligated to issue any securities.
• H.C. Wainwright's involvement is subject to satisfactory due diligence and internal approvals, and is on a reasonable best efforts basis.
• The agreement does not guarantee a successful offering or securing financing for Silo Pharma.
• Silo Pharma will compensate H.C. Wainwright with a cash fee of 7.5% of gross proceeds for offerings, but 3.0% for ATM takedowns.
• H.C. Wainwright will receive warrants equal to 7.5% of the shares placed in each offering, excluding ATMs, with an exercise price of 125% of the offering price.
• Silo Pharma will pay H.C. Wainwright a management fee of 1.0% of gross proceeds, $10,000 for non-accountable expenses, and up to $50,000 for legal counsel fees (increased to $100,000 for public offerings).
• H.C. Wainwright has a right of first refusal for 12 months following each offering to act as sole book-runner or placement agent for any financing or refinancing.
• The initial term of the engagement is 90 days, extendable by another 90 days if an offering is consummated within the initial term.
• The agreement includes standard clauses regarding confidentiality, indemnification, and governing law.
• An amendment to the engagement letter adjusts the non-accountable expense allowance to $10,000 and the closing costs to $10,000.

Sentiment

Score: 7

Explanation: The document is a standard legal agreement, so the sentiment is neutral. However, the agreement itself is a positive step for Silo Pharma as it secures an underwriter for potential future capital raises.

Positives

• Silo Pharma secures an exclusive underwriter, H.C. Wainwright, for potential securities offerings.
• The agreement provides flexibility for various types of offerings, including ATM facilities.
• H.C. Wainwright's right of first refusal could lead to continued collaboration on future financings.

Negatives

• Silo Pharma is obligated to pay fees and issue warrants to H.C. Wainwright, regardless of the success of any offering.
• The exclusivity arrangement restricts Silo Pharma from engaging other underwriters during the term of the agreement.
• The tail provision requires compensation to H.C. Wainwright for financings completed within 12 months after termination if investors were introduced by H.C. Wainwright.

Risks

• The agreement does not guarantee a successful offering or securing financing for Silo Pharma.
• Market conditions could impact the consummation of any offering.
• The fees and expenses associated with the agreement could be significant, regardless of the outcome of any offering.
• Failure to comply with FINRA rules could require amendments to the agreement.

Future Outlook

The document outlines the terms for potential future securities offerings by Silo Pharma, with H.C. Wainwright acting as the exclusive underwriter. The actual occurrence and terms of these offerings are subject to mutual agreement and market conditions.

Management Comments

• Eric Weisblum, CEO of Silo Pharma, is the primary contact for the engagement.
• Management is expected to be available to answer inquiries from prospective investors prior to signing any purchase agreement.

Industry Context

This agreement is typical in the biotech industry, where companies frequently raise capital through securities offerings to fund research and development. H.C. Wainwright is a well-known underwriter for small-cap and micro-cap companies in the life sciences sector.

Comparison to Industry Standards

• The fees and warrant coverage outlined in the agreement are within the typical range for similar engagements in the biotech industry.
• Comparable companies raising capital through similar offerings often include similar terms for underwriter compensation and rights of first refusal.
• The specific terms of each offering will likely be influenced by market conditions and the company's valuation at the time of the offering.

Stakeholder Impact

• Shareholders may be impacted by potential dilution from the issuance of new securities and warrants.
• The company's ability to raise capital could impact its ability to fund research and development, affecting employees and other stakeholders.

Next Steps

• Silo Pharma and H.C. Wainwright will need to mutually agree on the terms of any specific securities offering.
• H.C. Wainwright will conduct due diligence on Silo Pharma.
• Silo Pharma may proceed with a securities offering subject to market conditions and internal approvals.

Key Dates

Keywords

underwriter, securities offering, H.C. Wainwright, Silo Pharma, engagement letter, ATM facility, financing